SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    G. Y. H. Lip, J. L. Halperin, P. Petersen, G. M. Rodgers, D. Pall, R. W. Renfurm, A Phase II, double-blind, randomized, parallel group, dose-finding study of the safety and tolerability of darexaban compared with warfarin in patients with non-valvular atrial fibrillation: the oral factor Xa inhibitor for prophylaxis of stroke in atrial fibrillation study 2 (OPAL-2), Journal of Thrombosis and Haemostasis, 2015, 13, 8
  2. 2
    Dorien Groenendaal, Gregory Strabach, Alberto Garcia-Hernandez, Takeshi Kadokura, Marten Heeringa, Roelof Mol, Charlotte Eltink, Hartmut Onkels, The pharmacokinetics of darexaban (YM150), an oral direct factor Xa inhibitor, are not affected by ketoconazole, a strong inhibitor of CYP3A and P-glycoprotein, Clinical Pharmacology in Drug Development, 2014, 3, 3
  3. 3
    Takeshi Kadokura, Makoto Kashiwa, Dorien Groenendaal, Marten Heeringa, Roelof Mol, Frank Verheggen, Alberto Garcia-Hernandez, Hartmut Onkels, Clinical pharmacokinetics, pharmacodynamics, safety and tolerability of darexaban, an oral direct factor Xa inhibitor, in healthy Caucasian and Japanese subjects, Biopharmaceutics & Drug Disposition, 2013, 34, 8
  4. 4
    Gentian Denas, Vittorio Pengo, Investigational anticoagulants for hematological conditions: a new generation of therapies, Expert Opinion on Investigational Drugs, 2013, 22, 10, 1281

    CrossRef

  5. 5
    Amir Aziz, Shabeena Aziz, Stephen B. Wheatcroft, Novel anti-thrombotic therapy in acute coronary syndromes, Cor et Vasa, 2013, 55, 2, e117

    CrossRef